FLT3 and acute myeloid leukemia: In 231 FLT3-ITD-mutated AML patients receiving postinduction therapy with either chemotherapy and autologous or allogeneic HSCT, a trend toward a higher cumulative incidence of relapse (CIR) for ITDs at the TKD1 level was described.